ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical and Diagnostic Microbiology and Immunology
This article is part of the Research TopicThe Role of Cellular Signaling and Immune Regulation in the Bone Marrow Microenvironment in Infectious Bone Diseases: Mechanism Insights and TreatmentView all articles
Bone and joint tuberculosis: clinical manifestation, diagnostic techniques and drug resistance analysis
Provisionally accepted
Yingying Yuan
Pengxiang LiXiang jie QiuHonghua ZhangHao ChenNan ZangWenbo LiMeijin ChengZhen GuoXiaodong NiuYue ZhaoXiuli Cao
YUNGANG HAN
Wei Wang*- Henan Provincial Chest Hospital, Zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: Clinical data on bone and joint tuberculosis (BJTB) in developing countries remain limited. This study aims to investigate the clinical, epidemiological, and drug-resistance characteristics of BJTB patients in Central China and to optimize diagnostic strategies. Methods: This retrospective study analyzed data from patients diagnosed with BJTB at Henan Provincial Chest Hospital between 2016 and 2022. Results: Among the 902 patients, 518 (57.4%) were male and 384 (42.6%) were female. The age groups of 21-30 years and 51-60 years, as well as the rural population, showed the highest prevalence of cases. Local pain was the most prevalent symptom, followed by fever, night sweats, and neurological dysfunction. On average, the time from symptom onset to diagnosis was 6.1 months, and the mean hospital stay was 64.2 days. Spinal tuberculosis was the most frequently affected site, accounting for 77.6% (700/902) of cases. Five diagnostic techniques were evaluated, with GeneXpert MTB/RIF demonstrating superior performance by achieving a sensitivity of 91.6% (95%CI: 86.3%-95.0%) and specificity of 90.1% (95%CI: 85.5%-93.6%). Unlike drug resistance patterns observed in other regions, streptomycin (29.6%) and rifabutin (18.2%) were the most frequently encountered first-line and second-line anti-tuberculosis drugs, respectively. The prevalence of multidrug-resistant tuberculosis (MDR-TB) was 8.3% (95% CI: 5.1%–13.2%), and extensively drug-resistant tuberculosis (XDR-TB) was identified in 1.6% (95% CI: 0.2%-5.6%) of cases. Conclusions: The application of GeneXpert MTB/RIF demonstrated significant diagnostic accuracy for BJTB. The control of MDR-TB remains a critical challenge in the management of BJTB in Central China.
Keywords: Bone & Joint tuberculosis, Drug Resistance, GeneXpert MTB/RIF, Mycobacterium tuberculosis, Osteoarticular tuberculosis
Received: 18 Aug 2025; Accepted: 05 Nov 2025.
Copyright: © 2025 Yuan, Li, Qiu, Zhang, Chen, Zang, Li, Cheng, Guo, Niu, Zhao, Cao, HAN and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Wang, jyk2785@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.